78.2 F
New York
Tuesday, June 6, 2023



Vesalio Initiates Clinical Study Evaluating Innovative Thrombectomy Technique for Patients with STEMI

Related Articles

UTRS Expands Civil/Environmental Engineering and Surveying Capabilities Into Northern New Jersey Through Acquisition

Cherry Hill, NJ, June 02, 2023 --(PR.com)-- Universal Technical Resource Services, Inc. (UTRS), a leading provider of engineering services and information technology, today announced the...

New Research Benchmarks Biopharmaceutical Perceptions of Global CRO Thought Leadership

Menlo Park, CA, June 01, 2023 --(PR.com)-- Life Science Strategy Group (LSSG), the leading strategic consulting firm to the CRO industry, is pleased to announce...
Nashville, TN, December 23, 2021 –(PR.com)– Today, Vesalio announced the start of enrollment in its NATURE study using enVast™, the company’s first thrombectomy system for patients presenting with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention.

NATURE is a randomized, multi-center clinical trial comparing the safety and efficacy of enVast™ as an adjunctive measure to conventional intervention versus the standard of care in STEMI patients with large thrombus burden.

The first patient in the study was enrolled by Professor Marco Valgimigli, Deputy Chief of Cardiology at Cardiocentro Ticino Istituto, in Lugano, Switzerland.

“Our first-in-human case series of 61 STEMI patients with large thrombus burden allowed us to develop a safe and effective thrombectomy technique using the enVast™ stent retriever under continuous aspiration. With the NATURE study, our goal is to…

Read more…

Popular Articles